Sanofi, As­traZeneca and two lead­ing trade groups want clar­i­ty around an ap­pel­late de­ci­sion that called for Te­va to delist five in­haler patents from the FDA … ...

Nick Chubb speaks on his future with free agency pending Box Office: ‘Dog Man' Still Off the Leash at No. 1, ‘Heart Eyes' and ‘Love Hurts' Beat Slowly in Quiet Super Bowl Weekend ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Dorie Chevlen Dorie Chevlen is a writer covering home design. Her ...

Last Friday, AI startup OpenAI filed a new application to trademark products associated with its brand — “OpenAI” — with the U.S. Patent and Trademark Office (USPTO). Normally, this wouldn ...

L’Oreal OR-1.27%decrease; red down pointing triangle will sell part of its stake in Sanofi SAN-0.21%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L’Oréal. This transaction is part of Sanofi’s share buyback program ...

Sanofi is planning a $5.12bn share buyback programme in 2025. Image credit: Shutterstock / JHVEPhoto. Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L’Oréal, the first of ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

Sanofi SAN-1.58%decrease; red down pointing triangle forecast stronger earnings growth this year and said it planned to launch a $5.2 billion share buyback. The French pharmaceutical company said ...

Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers ...